Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2016-08-08 Report Publication Anno…
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Dato for offentliggørelse af delårsrapport for første halvår (Q2) 2016 for ALK
Report Publication Announcement Classification · 91% confidence The document is a press release announcing that ALK will publish its interim (half-year/Q2 2016) report on August 16, 2016 and will host a conference call. It does not contain the actual interim financial statements or detailed results, but merely states the publication date and call logistics. Therefore, it is a Report Publication Announcement.
2016-08-08 Danish
Dato for offentliggørelse af delårsrapport for første halvår (Q2) 2016 for ALK
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1284 characters) informing investors about the upcoming release date of the six-month interim report (Q2 2016) and the details for the associated conference call. Per the 'Menu vs Meal' rule, since this is an announcement regarding the publication of a report rather than the report itself, it is classified as a Report Publication Announcement.
2016-08-08 English
M&A Activity 2016
M&A Activity Classification · 99% confidence The document is titled "Selskabsmeddelelse nr. 22/2016" (Company Announcement no. 22/2016) and dated July 26, 2016. It details a significant corporate event: ALK taking back rights to SLIT tablets in North America from MSD. This is a material corporate action announcement, not a full financial report (like 10-K or IR) or a standard earnings release (ER). It is a specific announcement regarding a change in business structure/agreements, which often falls under general regulatory announcements or specific transaction/financing categories. Given the nature of the announcement—a major change in commercial rights and partnership termination—it is best classified as a general Regulatory Filing (RNS) as it is a formal, non-periodic company announcement that doesn't fit the more specific categories like M&A (TAR) or Capital Change (CAP). The document also mentions the upcoming 'halvårsrapport' (interim report) on August 16, confirming this document is *not* the interim report itself.
2016-07-26 English
M&A Activity 2016
M&A Activity Classification · 99% confidence The document announces a significant change in a strategic partnership where rights to allergy immunotherapy tablets (GRASTEK®, RAGWITEK®) are reverting from MSD back to ALK for North America. This involves changes in commercialization strategy and financial implications (milestone payments, royalties). This type of announcement, detailing a major corporate/strategic event that impacts future business operations and potentially financing/structure, fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were purely informational. However, since it details the termination of a major agreement and the resulting strategic shift, it is a significant corporate action announcement. It is not a standard earnings release (ER), interim report (IR), or annual report (10-K). It is a material event disclosure regarding business structure and future strategy, which often falls under general corporate announcements. Given the options, 'Capital/Financing Update (CAP)' covers changes in strategic agreements that affect future revenue streams and structure, or 'Regulatory Filings (RNS)' as a general material event disclosure. Since it is a specific announcement about the termination of a partnership and the reversion of rights, which is a major corporate event, and it is not explicitly about raising capital or debt, I will classify it as a general material announcement, which aligns best with RNS, as it doesn't fit the specific financial/governance codes perfectly, but it is a formal disclosure. Upon re-evaluation, this is a material corporate event disclosure regarding a major business agreement termination, which is often classified under general regulatory announcements if no other specific category (like M&A/TAR) applies. Since it is a formal press release announcing a material change in business structure, RNS is the most appropriate fallback for a significant, non-standard filing event. The document ends by mentioning the upcoming 'six-month interim report (Q2) on 16 August,' confirming this document itself is an announcement, not the report itself, supporting the non-report classification.
2016-07-26 English
ALK overtager rettighederne til SLIT-tabletter i Nordamerika fra MSD
Regulatory Filings Classification · 18% confidence The document is a corporate press release announcing the termination of a partnership and transfer of product rights from MSD back to ALK, along with strategic plans for North America. It does not contain financial statements, investment data, voting results, director changes, dividends, or regulatory filings, nor is it an M&A takeover or financing round. It is a general business update that does not fit any specific category, so it falls into the fallback category: Regulatory Filings (RNS).
2016-07-26 Danish
ALK overtager rettighederne til SLIT-tabletter i Nordamerika fra MSD
Regulatory Filings Classification · 95% confidence The document is a corporate announcement regarding a change in business strategy and the termination of a partnership agreement between ALK and MSD. It details the reversion of rights for specific products, the strategic implications for the company, and confirms that the transaction has no impact on the full-year outlook. It does not fit into specific categories like '10-K' (annual report), 'CT' (transcript), or 'RPA' (announcement of a report). Since it is a general corporate announcement regarding business operations and strategic partnerships, it falls under the 'RNS' (Regulatory Filings) category as a general regulatory announcement.
2016-07-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.